Advances in technology, such as new antimicrobial drugs and new equipment, have led to an increased interest in home intravenous antibiotic therapy (HIVAT) in The Netherlands. The aim of this study was to evaluate HIVAT in terms of costs, effectiveness and patient experience. Seventy-five patients with an infectious disease were treated by a transmural intravenous antibiotic therapy (TIVAT) programme at home for approximately 2000 days. An individual protocol and training was given to each patient and the care givers so that patients could perform the home treatment themselves with, in most cases, the help of family and friends. Optimal use was made of existing health care structures like hospital facilities, pharmacies and the general practitioner. TIVAT is an example of intensive home care. Preliminary data show that it seems safe, effective and cost-efficient with positive patient experiences. A once-daily dosage regimen of the antimicrobial agent was preferable.